MindMed to Participate in Upcoming Investor Conferences

Business Wire

13 Nov 2024

NEW YORK, November 13, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

Jefferies London Healthcare Conference
- Format: 1x1 Meetings
- Dates: November 20-21, 2024
- Location: London, UK
7^th Annual Evercore HealthCONx Conference
- Format: Fireside Chat and 1x1 Meetings
- Date and Time: Thursday, December 5, 2024 at 11:15 PM ET
- Location: Coral Gables, FL
- Webcast Link: 7^th Annual Evercore HealthCONx Conference

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113954608/en/

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483984006"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483984006\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2483984006?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/o4lcCioA9IKD5ETC6zC.Cw--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/475aa792b60c2597e7242e5c1faf854c","is_english":true,"pubTime":"2024-11-13 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483984006","market":"us","top_or_hot":-1,"title":"MindMed to Participate in Upcoming Investor Conferences","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"403\" src=\"https://s1.yimg.com/uu/api/res/1.2/Q5joP5497ksB_WlcjXPcug--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/475aa792b60c2597e7242e5c1faf854c\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>NEW YORK, November 13, 2024</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:</p>\n<ul>\n<li><b>Jefferies London Healthcare Conference</b>\n<ul>\n<li>Format: 1x1 Meetings</li>\n<li>Dates: November 20-21, 2024</li>\n<li>Location: London, UK</li>\n</ul></li>\n<li><b>7<sup>th</sup> Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference</b>\n<ul>\n<li>Format: Fireside Chat and 1x1 Meetings</li>\n<li>Date and Time: Thursday, December 5, 2024 at 11:15 PM ET</li>\n<li>Location: Coral Gables, FL</li>\n<li>Webcast Link: 7<sup>th</sup> Annual Evercore HealthCONx Conference</li>\n</ul></li>\n</ul>\n<p>Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.</p>\n<p><b>About MindMed</b></p>\n<p>MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241113954608/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>For Media:</b> media@mindmed.co <br/><b>For Investors:</b> ir@mindmed.co<br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed to Participate in Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mindmed-participate-upcoming-investor-conferences-120000102.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, November 13, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mindmed-participate-upcoming-investor-conferences-120000102.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://finance.yahoo.com/news/mindmed-participate-upcoming-investor-conferences-120000102.html","article_id":"2483984006","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/o4lcCioA9IKD5ETC6zC.Cw--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/475aa792b60c2597e7242e5c1faf854c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483984006","pubTimestamp":1731499200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NEW YORK, November 13, 2024----Mind Medicine  Inc.  , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:. Date and Time: Thursday, December 5, 2024 at 11:15 PM ET. Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF","MNMD":"Mind Medicine (MindMed) Inc.","BK4007":"制药","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF"},"translate_title":"MindMed将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.61,"MNQmain":0.6,"NQmain":0.6,"MNMD":0.9,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"NEW YORK, November 13, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:\n\nJefferies London Healthcare Conference\n\nFormat: 1x1 Meetings\nDates: November 20-21, 2024\nLocation: London, UK\n\n7th Annual Evercore HealthCONx Conference\n\nFormat: Fireside Chat and 1x1 Meetings\nDate and Time: Thursday, December 5, 2024 at 11:15 PM ET\nLocation: Coral Gables, FL\nWebcast Link: 7th Annual Evercore HealthCONx Conference\n\n\nAudio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.\nAbout MindMed\nMindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241113954608/en/\nContacts\nFor Media: media@mindmed.co For Investors: ir@mindmed.co","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}